Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $41.79 to $44.15
• 50-Day Range: $37.92 to $47.96
• 52-Week Range: $37.39 to $63.00
• Volume: 574,214 shs
• Average Volume: 407,957 shs
• Market Capitalization: $2.19 billion
• P/E Ratio: 725.45
• Dividend Yield: N/A
• Price Target: $60.86
• Consensus Rating: Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 52% of companies evaluated by MarketBeat, and ranked 513th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vericel has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 214.29%

Earnings Growth

Earnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 725.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 725.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.80.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 9.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.18% of the outstanding shares of Vericel have been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Vericel has recently increased by 2.90%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.18% of the outstanding shares of Vericel have been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Vericel has recently increased by 2.90%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.42

News Sentiment

Vericel has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Vericel this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for VCEL on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,258,348.00 in company stock.

Percentage Held by Insiders

Only 5.20% of the stock of Vericel is held by insiders.

VCEL Stock Analysis - Frequently Asked Questions

How have VCEL shares performed this year?

Vericel's stock was trading at $54.91 at the start of the year. Since then, VCEL shares have decreased by 20.7% and is now trading at $43.52.
View the best growth stocks for 2025 here.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.14. The company's revenue was up 2.6% compared to the same quarter last year.
Read the conference call transcript.

Who are Vericel's major shareholders?

Vericel's top institutional investors include Vanguard Group Inc. (6.97%), Invesco Ltd. (4.53%), Conestoga Capital Advisors LLC (4.11%) and Congress Asset Management Co. (2.95%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn.
View institutional ownership trends.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/21/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 300
• Year Founded: 1989

Price Target and Rating

• Average Stock Price Target: $60.86
• High Stock Price Target: $67.00
• Low Stock Price Target: $51.00
• Potential Upside/Downside: +39.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.03
• Trailing P/E Ratio: 725.45
• Forward P/E Ratio: 310.86
• P/E Growth: N/A
• Net Income: $-3,180,000.00
• Net Margins: 1.56%
• Pretax Margin: 2.05%
• Return on Equity: 1.48%
• Return on Assets: 0.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.61
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $238.54 million
• Price / Sales: 9.18
• Cash Flow: $0.01 per share
• Price / Cash Flow: 3,081.95
• Book Value: $4.73 per share
• Price / Book: 9.20

Miscellaneous

• Outstanding Shares: 50,343,000
• Free Float: 46,791,000
• Market Cap: $2.19 billion
• Optionable: Optionable
• Beta: 1.31